Abla Creasey, PhD
Abla is a distinguished leader in regenerative medicine with over 40 years of experience in therapeutic development, regulatory strategy, and collaborative partnerships. As Vice President of Therapeutics at California Institute for Regenerative Medicine, she led over 100 clinical-stage programs and managed a $300M+ portfolio across oncology, neurology, and rare diseases. Abla has been instrumental in achieving accelerated FDA designations, fostering cross-sector collaborations within pharma, and translating biotech research into patient-ready therapies. With 23 patents, 50+ publications, and prior leadership roles at Chiron and Johnson & Johnson, she brings unmatched regulatory, translational, and clinical development insight to One Patient One Cure.
Karl D. Hess
Karl is a digital health innovator and healthcare strategist with 25+ years of experience and over $20B in deal-making. From building population health platforms to deploying predictive analytics in clinical care, he has shaped over 100 digital ventures across diagnostics, therapeutics, genomics, and virtual care. As former CEO of Texas Health Aetna, Karl led digital expansion and accelerated growth. With roots in clinical research and executive leadership at Genentech and BD, Karl’s unique ability to merge science with market strategy makes him a critical guide for One Patient One Cure’s growth and impact.
Ruslan Rust, PhD
Ruslan is a rising leader in neuroscience and regenerative medicine, currently serving as Assistant Professor of Research Physiology and Neuroscience at the University of Southern California and Assistant Director of its Stem Cell Unit. He has received prestigious grants for his work on next-generation iPSC-derived cell sources for stroke and Alzheimer’s therapy, with research published in leading scientific journals. Ruslan’s expertise spans preclinical research and genomics, with a focus on improving the delivery and efficacy of cell-based therapeutics. His scientific vision and translational mindset position him to help One Patient One Cure pioneer brain-targeted personalized medicine.
Justin Smith, PhD
Justin offers a rare combination of nonprofit leadership, strategic engagement, and fundraising expertise. With a PhD in Leadership Studies and a record of raising over $500,000 in private donations, he has also grown enterprise SaaS revenue from $200K to $4M through data-informed customer success strategies. Justin excels in building relationships, enhancing donor stewardship, and aligning teams with mission-driven outcomes. His strategic and empathetic approach ensures One Patient One Cure continues to cultivate trust, expand its reach, and deliver on its global mission.
Jiawei Tang
Jiawei brings nearly 15 years of experience in the healthcare industry, with a focus on strategic planning, corporate operations, and international marketing. She spent over a decade in managerial roles at Pfizer and later served as a Business Strategy Advisor at Resolian. She now serves as Co-Founder and Chief Operating Officer of Global Biopharma Partnerships (GB-Partner), where she leads cross-border biopharma collaborations and growth strategy initiatives. Jiawei also plays an active role in nonprofit leadership as Secretary General of the Chinese Association for Science and Technology in the U.S. and as a Global Expansion Committee Member of the Healthcare Businesswomen’s Association, championing equitable healthcare access and women’s leadership in life sciences.
Jordan W. Henry, MHA, FAHM
Jordan is a results-oriented leader with a distinguished background in healthcare administration, managed care, and emergency management. Renowned for his ability to navigate complex systems and lead high-performing, cross-functional teams, he brings both strategic vision and operational depth to every initiative he undertakes. As an Advisory Board member, Jordan contributes his expertise to advance our mission of accelerating scientific discovery into real-world treatments. His deep understanding of healthcare systems and commitment to operational excellence strengthen our ability to deliver precision medicine to patients more efficiently and effectively. In addition, as the founder & AI Ethicist of Veritas AI Consulting Firm, Jordan is guiding One Patient One Cure through the critical landscape of AI governance, ethics, compliance, and operational strategy.
Jessicca M. Rege, PhD
Jessicca is an accomplished biotech executive with extensive leadership experience spanning C-suite roles. Her career is defined by a commitment to advancing life sciences and transforming innovative therapies into real-world solutions, with a proven track record of guiding organizations through all phases of drug development—from preclinical research to the commercialization of small molecules, biologics, and advanced therapeutics. Currently, as CEO of Sus Clinicals and CMO of OncoScope-AI, Jessicca drives innovation in preclinical research and AI-powered oncology solutions. As an Advisory Board member, Jessicca brings her wealth of experience to support One Patient One Cure in translating cutting-edge research and technology into lifesaving treatments for patients worldwide.
